AI News Sentiment & Analysis
Cogent Biosciences, Inc. (COGT) — AI News Sentiment & Analysis
4 recent AI analyses of Cogent Biosciences, Inc. (COGT) stock news and press releases, with sentiment and confidence scoring updated continuously.
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
BullishRegulatory DecisionSubmission of New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) to the FDA. (Timing: FDA decision likely within 6-10 months post-submission.)Jun 30, 2026Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
BullishClinical ResultsFDA approval of bezuclastinib combination for GIST patients following Priority Review acceptance. (Timing: November 30, 2026 (PDUFA date))May 30, 2026Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
BullishRegulatory DecisionFDA acceptance of New Drug Application (NDA) for bezuclastinib in GIST with Priority Review, setting a PDUFA date, builds on strong Phase 3 results. (Timing: PDUFA date is November 30, 2026.)May 28, 2026Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
BullishOral presentation of positive Phase 3 PEAK trial data for bezuclastinib in Gastrointestinal Stromal Tumors (GIST) at the ASCO Annual Meeting. (Timing: May 29 - June 2, 2026)Apr 21, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Cogent Biosciences, Inc. (COGT) bullish or bearish right now?
AI Sentiment on COGT: 4 Bullish.
What was the latest AI analysis for Cogent Biosciences, Inc. (COGT)?
The latest analysis was published on 6/30/2026 with the headline: "Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)".
How does Bekodia analyze Cogent Biosciences, Inc. (COGT) stock?
Bekodia uses advanced AI models to process Cogent Biosciences, Inc. (COGT) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.